Full Text View
Tabular View
No Study Results Posted
Related Studies
Dose-Intense Temozolomide in Recurrent Glioblastoma
This study is ongoing, but not recruiting participants.
Study NCT00657267   Information provided by Dana-Farber Cancer Institute

First Received on April 8, 2008.   Last Updated on March 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Glioblastoma
Gliosarcoma
More general conditions related to this trial
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
Temozolomide
Additional drug interventions recognized in this trial
Dacarbazine
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Patrick Y. Wen, MD
Brigham and Women's Hospital
Massachusetts General Hospital
University of Pennsylvania
Wake Forest University
Tufts Medical Center
Dartmouth-Hitchcock Medical Center
Schering-Plough


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services